| Cat. No. |
Product Name |
CAS No. |
Information |
| GY03925 |
Bay 41-4109 racemate
|
298708-79-9 |
The racemate form of Bay 41-4109, which is a potent, non-nucleosidic inhibitor of HBV nucleocapsid maturation with IC50 of 0.05 uM. |
| GY10289 |
NVR 3-778
|
1445790-55-5 |
NVR 3-778 (NVR3-778, NVR 3778) is a small molecule inhibitor of HBV replication that targets the viral core protein, a first-in-class capsid assembly modulator; inhibits the generation of infectious HBV DNA containing virus particles with EC50 of 0.40 uM in HepG2.2.15 cells; NVR 3-778 inhibits pgRNA encapsidation, viral replication and the production of HBV DNA- and HBV RNA-containing particles, also inhibits de novo infection and viral replication in primary human hepatocytes with EC50 of 0.81 uM against HBV DNA and 3.7-4.8 uM against the production of HBV antigens and intracellular HBV RNA; demonstrates favorable pharmacokinetics and safety in animal species. |
| GY06728 |
NTCP binder peptide WD1
|
|
NTCP binder peptide WD1 is a macrocyclic peptide, pan-genotypic inhibitor of HBV cellular entry via targeting the cell-surface receptor for HBV, sodium taurocholate cotransporting polypeptide (NTCP, Kd=15 nM), reduces HBs antigen levels in culture supernatants; also inhibits cellular entry by the related hepatitis D virus (HDV), and is active against diverse strains of HBV (including clinically relevant nucleos(t)ide analog-resistant and vaccine escaping strains); exhibitsno inhibition of NTCP-mediated bile acid uptake in contrast to other NTCP-binding HBV entry inhibitors. |
| GY06727 |
NTCP binder peptide WL4
|
|
NTCP binder peptide WL4 is a macrocyclic peptide, pan-genotypic inhibitor of HBV cellular entry via targeting the cell-surface receptor for HBV, sodium taurocholate cotransporting polypeptide (NTCP, Kd=42 nM), reduces HBs antigen levels in culture supernatants with IC50 of 0.66 uM; also inhibits cellular entry by the related hepatitis D virus (HDV), and is active against diverse strains of HBV (including clinically relevant nucleos(t)ide analog-resistant and vaccine escaping strains); exhibitsno inhibition of NTCP-mediated bile acid uptake in contrast to other NTCP-binding HBV entry inhibitors. |
| GY10005 |
JNJ-632
|
1572510-42-9 |
JNJ-632 (JNJ632) is a novel potent HVV capsid assembly modulator and HBV replication inhibitor with EC50 of 100-200 nM for genotypes A-D; does not show cytotoxicity for HepG2 cells (CC50>100 uM); dose-dependently reduces intracellular HBV RNA levels as well as HBe/cAg and HBsAg levels in the cell culture supernatant. |
| GY06088 |
Morphothiadin
|
1092970-12-1 |
Morphothiadin(GLS4) is a potent inhibitor of HBV capsid assembly, inhibits HBV replication (EC50=62.24 nM) and reduces HBV-DNA levels in HepG.2.2.15 cells (IC50=14 nM), shows efficacy against ADV-resistant HBV mutations; strongly inhibits core gene expression (at 100 to 200 nM), suppresses virus accumulation in the supernantant of HepAD38 cells; inhibits HBV replicative forms in the live, shows strong and sustained suppression of virus DNA in treated mice. |
| GY05997 |
AB-423
|
1572510-80-5 |
AB-423 is a novel potent, class II HBV capsid inhibitor that shows potent inhibition of HBV replication with EC50 of 0.08-0.27 uM, with no significant cytotoxicity (CC50>10 uM); inhibits HBV genotypes A through D and nucleos/tide-resistant variants, causes capsid particles devoid of encapsidated pgRNA and rcDNA in treated HepDES19 cells, prevents the conversion of encapsidated rcDNA to cccDNA presumably by interfering with the capsid uncoating process; dose-dependently reduces serum HBV DNA levels in mouse model of HBV model, shows synergistic antiviral activity combined with entecavir (ETV). |
| GY05994 |
RO6889678
|
1578153-27-1 |
RO6889678(RO 6889678) is a highly potent inhibitor of HBV capsid formation with attributes that are favorable for targeting the liver, whilst maintaining moderate peripheral exposure. |
| GY05862 |
Isothiafludine
|
960527-22-4 |
Isothiafludine (NZ-4) is a novel HBV capsid assembly inhibitor that inhibits HBV replication through blocking pregenomic RNA encapsidation, suppresses HBV replication in HepG2.2.15 cells with IC50 of 1.33 uM; shows activity against the replication of various drug-resistant HBV mutants, including 3TC/ETV-dual-resistant and ADV-resistant HBV mutants; concentration-dependently reduces the encapsidated HBV pgRNA, resulting in the assembly of replication-deficient capsids in HepG2.2.15 cells; inhibits DHBV DNA replication in the DHBV-infected ducks after oral administration. |
| GY05771 |
RG7834
|
2072057-17-9 |
RG7834 (RO 7020322) is a highly selective and orally bioavailable HBV inhibitor, potently inhibits HBV antigens (both HBsAg and HBeAg) and HBV DNA, with IC50s of 2.8, 2.6, and 3.2 nM, respectively, in dHepaRG Cells |
$ USD
Select Your Country or Region
